Search research articles
Contact Us
Filters
Showing results (71-80 of 153) with videos related to
Page
of 16
Sort By:
Journal of Health Economics and Outcomes Research
|
February 5, 2024
Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease
Adrian Peacock, Frances C Dehle, Oscar A Mesa Zapata, et al.
Leukemia & Lymphoma
|
November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Nicole Wong Doo, Philip A Thompson, H Miles Prince, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2016
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
Simon J Harrison, Paul Mainwaring, Timothy Price, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Blood
|
July 31, 2014
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer, Sung-Soo Yoon, Simon J Harrison, et al.
Epigenomics
|
November 8, 2012
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))
Simon J Harrison, Mark Bishton, Susan E Bates, et al.
Frontiers in Oncology
|
February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
P Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Blood Advances
|
July 19, 2023
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Gemma Reynolds, Edward R Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 25, 2014
Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss
Julie M Quach, Maria Askmyr, Tanja Jovic, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 153) with videos related to
Sort By:
Page
of 16
Journal of Health Economics and Outcomes Research
|
February 5, 2024
Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease
Adrian Peacock, Frances C Dehle, Oscar A Mesa Zapata, et al.
Leukemia & Lymphoma
|
November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Nicole Wong Doo, Philip A Thompson, H Miles Prince, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 28, 2016
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
Simon J Harrison, Paul Mainwaring, Timothy Price, et al.
Expert Review of Hematology
|
October 13, 2025
Updated guidelines in the treatment of myeloma bone disease in 2025: consensus statement by the Medical and Scientific Advisory Group of Australia (MSAG) to Myeloma Australia
Angelina Yong, Kate Vandyke, Bradley Augustson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 15, 2025
New Zealand Multiple Myeloma Patients Demonstrate Inferior Outcomes When Compared to Australian Counterparts - A Retrospective Cohort Study from the Myeloma and Related Diseases Registry (MRDR)
Jian Li, Yayehirad Melsew, Cameron Wellard, et al.
Blood
|
July 31, 2014
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer, Sung-Soo Yoon, Simon J Harrison, et al.
Epigenomics
|
November 8, 2012
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®))
Simon J Harrison, Mark Bishton, Susan E Bates, et al.
Frontiers in Oncology
|
February 5, 2025
Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia
P Joy Ho, Hang Quach, M Hasib Sidiqi, et al.
Blood Advances
|
July 19, 2023
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Gemma Reynolds, Edward R Scheffer Cliff, Ghulam Rehman Mohyuddin, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
November 25, 2014
Myelosuppressive therapies significantly increase pro-inflammatory cytokines and directly cause bone loss
Julie M Quach, Maria Askmyr, Tanja Jovic, et al.
Page
of 16